Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP Versus CEOP-induced Cardiotoxicity in Aggressive B-cell Lymphoma
NCT00854568Phase 3Completed
- Sponsor
- Fudan University
- Start
- Mar 2009
- Primary completion
- Dec 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin in aggressive B-cell lymphoma, sponsored by Fudan University. Started Mar 2009; status: completed.
02
Drugs
epirubicin
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT00854568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854568.